/Companies

Hemanext

Lexington, US · Delaware corporation · 5 known investors

Find your way into Hemanext

683 people in our graph share verified history with the Hemanext team — schools, employers, funds. One of them is your warm intro.

Danielle Abdelahadunlockedknows Daan Kok · together at Bluebird Bio (overlapped)
×11knows the team · via A.T. Kearney Management Consulting

Hemanext develops oxygen-controlled storage technology to preserve red blood cell quality and function during transfusion storage. The company serves hospitals and blood establishments seeking to improve patient outcomes in transfusion medicine.

Founders & leadership

MCMartin Cannon
Martin CannonFounder and former CEOMartin Cannon held senior positions at Bain & Company and A.T. Kearney focused on healthcare and transfusion medicine before founding Hemanext, which develops oxygen-controlled storage technology for preserving red blood cells during transfusion.
JBJill Buckley
Jill BuckleyVice President Human Resources2019–2025Jill Buckley is Vice President of Human Resources at Hemanext, bringing experience in HR leadership across startups and larger organizations in multiple industries.
DKDaan Kok
Daan KokHead of BD and Strategy2024–2026Daan Kok holds a master's degree in International Business Studies and a chartered management accountant credential. He brings extensive experience in biotech and medtech across finance, sales, marketing, regulatory, and general management roles in Europe and the United States, including founding a consulting company.
RH
Robert HaimeVice President of Commercial Operations2023–2025Robert Haime holds an Industrial Engineering background and brings over 25 years of experience in blood banking, transfusion medicine, and medical devices, including roles in manufacturing, product management, and commercial leadership. He previously commercialized the Acrodose Platelet System and scaled manufacturing operations for healthcare technology platforms.
RCRafael Cordero
Rafael CorderoVP of Product Development2014–2017Rafael Cordero held product development and design roles at medical device companies including Aspect Medical, where he worked on monitoring systems, and at Innovasea in aquaculture technology. He is Vice President of Product Development at Hemanext, which develops oxygen-controlled storage systems for red blood cell preservation.
MBMichael Bavonese
Michael BavoneseExecutive
AD
Andrew DunhamNamed on SEC filing

Board

SE
Stephen EckertChairman of the Board of Directors
PP
Philip PeadBoard director
GC
Geoffrey CrouseBoard director
WP
William Patrick O'NeillBoard director
EA
Eduardo AvayuBoard director

Investors · 5

Also in the syndicate · 5

Antaeus Enterprises, Inc.Grabe Family OfficeOmega Family OfficeThe Eduardo Avayu Family OfficeThe Testa Family Office

Funding

SEC filings, press & company announcements

$122.3M disclosed across 8 of 10 rounds · 2016–2025

  • Undisclosed amountSeries ASep 2021

    Antaeus Enterprises, Inc., Grabe Family Office, Omega Family Office, The Eduardo Avayu Family Office, The Testa Family Office

    Source ↗
▶$20MraisedAug 2025 · 29 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert HaimeExecutive Officer
  • Eric J. NewmanExecutive Officer
  • Peter TestaDirector
  • Daan KokExecutive Officer
  • Paul M. NessDirector
  • Geoffrey CrouseDirector
  • Andrew DunhamExecutive Officer, Director
  • Laura DanielsExecutive Officer
  • Eduardo AvayuDirector
  • Philip PeadDirector
  • Stephen A. EckertDirector
  • Joseph GroganDirector
  • Laurel OmertExecutive Officer
  • Ismail KolaDirector
  • William Patrick O'NeillDirector
  • Jill BuckleyExecutive Officer
Offering amount
$24M
Amount sold
$20M
Sales commissions
$41.3K
Placement agents
Octavian AG
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.7MraisedJul 2025 · 51 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen A. EckertDirector
  • Philip PeadDirector
  • Geoffrey CrouseDirector
  • William Patrick O'NeillDirector
  • Jill BuckleyExecutive Officer
  • Eduardo AvayuDirector
  • Peter TestaDirector
  • Daan KokExecutive Officer
  • Robert HaimeExecutive Officer
  • Paul M. NessDirector
  • Ismail KolaDirector
  • Andrew DunhamExecutive Officer, Director
  • Eric J. NewmanExecutive Officer
  • Joseph GroganDirector
  • Laura DanielsExecutive Officer
  • Laurel OmertExecutive Officer
Offering amount
$21.7M
Amount sold
$21.7M
Sales commissions
$27.2K
Placement agents
Octavian AG
First sale
Nov 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJan 2024 · 10 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Stephen A. EckertDirector
  • Paul M. NessDirector
  • Andrew DunhamExecutive Officer, Director
  • Robert HaimeExecutive Officer
  • Laurel OmertExecutive Officer
  • Michael David TestaDirector
  • Laura DanielsExecutive Officer
  • Daan KokExecutive Officer
  • William Patrick O'NeillDirector
  • Eduardo AvayuDirector
  • Ismail KolaDirector
  • Eric J. NewmanExecutive Officer
  • Jill BuckleyExecutive Officer
  • Richard PerleDirector
Offering amount
$10M
Amount sold
$5M
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.3MraisedNov 2023 · 20 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jill BuckleyExecutive Officer
  • Andrew DunhamExecutive Officer, Director
  • William Patrick O'NeillDirector
  • Daan KokExecutive Officer
  • Laurel OmertExecutive Officer
  • Laura DanielsExecutive Officer
  • Ismail KolaDirector
  • Richard PerleDirector
  • Eduardo AvayuDirector
  • Stephen A. EckertDirector
  • Robert HaimeExecutive Officer
  • Paul M. NessDirector
  • Eric NewmanExecutive Officer
  • Michael David TestaDirector
Offering amount
$11.3M
Amount sold
$11.3M
Finders' fees
$400K
Placement agents
Sonenshine & Company LLC
First sale
Jun 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.2MraisedFeb 2023 · 38 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin A. CannonExecutive Officer, Director
  • Daan KokExecutive Officer
  • Eric NewmanExecutive Officer
  • Michael David TestaDirector
  • Guy CoganDirector
  • Andrew DunhamExecutive Officer
  • William Patrick O'NeillDirector
  • Kimberly DorschExecutive Officer
  • Jill BuckleyExecutive Officer
  • Ismail KolaDirector
  • Eduardo AvayuDirector
  • Richard PerleDirector
  • Robert HaimeExecutive Officer
  • Paul M. NessDirector
  • Alex MarichalExecutive Officer
  • Stephen EckertDirector
  • Laurel OmertExecutive Officer
  • Laura DanielsExecutive Officer
Offering amount
$15M
Amount sold
$13.2M
Finders' fees
$1.1M
Placement agents
Sonenshine & Company LLC
First sale
Jul 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$39.6MraisedOct 2021 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Eric NewmanExecutive Officer
  • Guy CoganDirector
  • Laura DanielsExecutive Officer
  • Michael David TestaDirector
  • William Patrick O'NeillDirector
  • Andrew DunhamExecutive Officer
  • Laurel OmertExecutive Officer
  • Eduardo AvayuDirector
  • Stephen EckertDirector
  • Richard PerleDirector
  • Jill BuckleyExecutive Officer
  • Robert HaimeExecutive Officer
  • Alex MarichalExecutive Officer
  • Paul M. NessDirector
  • Martin A. CannonExecutive Officer, Director
Offering amount
$59.5M
Amount sold
$39.6M
Finders' fees
$1.1M
Placement agents
Sonenshine & Company LLC
First sale
Aug 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$8.8MraisedOct 2018 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard PerleDirector
  • Martin A. CannonExecutive Officer, Director
  • Stephen EckertDirector
  • Guy CoganDirector
  • David HermanDirector
  • Eric NewmanExecutive Officer
  • Michael David TestaDirector
  • Joseph BarrettExecutive Officer
Offering amount
$16M
Amount sold
$8.8M
First sale
Feb 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.7MraisedDec 2017 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin A. CannonExecutive Officer, Director
  • Michael David TestaDirector
  • David HermanDirector
  • Lynn MallettExecutive Officer
  • Joseph BarrettExecutive Officer
  • Guy CoganDirector
  • Stephen EckertDirector
  • Richard PerleDirector
Offering amount
$5M
Amount sold
$2.7M
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Hemanext for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Hemanext do?
Hemanext develops oxygen-controlled storage technology to preserve red blood cell quality and function during transfusion storage. The company serves hospitals and blood establishments seeking to improve patient outcomes in transfusion medicine.
Who founded Hemanext?
Hemanext was founded by Martin Cannon.
How much funding has Hemanext raised?
Hemanext has disclosed $122.3M raised across 8 of its 10 known rounds.
Where is Hemanext headquartered?
Hemanext is headquartered in Lexington, US.